WeightWatchers’ stock leaps as weight-loss-drug subscriptions boost revenue - MarketWatch
1. WW reported better-than-expected Q2 revenue amid GLP-1 treatment demand. 2. Stock down 8% post-results, but up 30.3% since bankruptcy exit. 3. Revenue declined 6.4% YoY, yet clinical business grew 55%. 4. WW aims to expand into menopause-focused health solutions. 5. Company revised full-year revenue guidance between $685M and $700M.